Literature DB >> 17331540

Progression in multiple sclerosis: further evidence of an age dependent process.

Marcus Koch1, Jop Mostert, Dorothea Heersema, Jacques De Keyser.   

Abstract

The relapsing-remitting phase and the progressive phase of multiple sclerosis (MS) seem to be the result of distinct pathophysiological processes. Previous research on the natural history of MS was largely focussed on relapses and disability scores. In this study we evaluated 438 patients with secondary or primary progressive MS. The influence of gender, initial disease course, onset manifestation and age at disease onset on age at progression and time to progression were evaluated with Kaplan-Meier survival analysis and Cox multivariate regression models. The analysis of these data showed that the initial disease course (SPMS or PPMS) had no influence on the age at progression. Gender had no influence on age at progression in PPMS and SPMS patients nor on time to progression in SPMS patients. PPMS patients with visual or brainstem/cerebellar onset had a significantly younger age at progression. SPMS patients with motor onset had a significantly higher age at progression and longer time to progression. Time to progression was significantly shorter in SPMS patients with higher age at disease onset. Our data give further support to the notion that progression in MS is an age dependent process independent of relapses.

Entities:  

Mesh:

Year:  2007        PMID: 17331540     DOI: 10.1016/j.jns.2007.01.067

Source DB:  PubMed          Journal:  J Neurol Sci        ISSN: 0022-510X            Impact factor:   3.181


  22 in total

1.  Relapses and disability accumulation in progressive multiple sclerosis.

Authors:  M Mateo Paz Soldán; Martina Novotna; Nuhad Abou Zeid; Nilufer Kale; Melih Tutuncu; Daniel J Crusan; Elizabeth J Atkinson; Aksel Siva; B Mark Keegan; Istvan Pirko; Sean J Pittock; Claudia F Lucchinetti; Brian G Weinshenker; Moses Rodriguez; Orhun H Kantarci
Journal:  Neurology       Date:  2014-11-14       Impact factor: 9.910

2.  Onset of progressive phase is an age-dependent clinical milestone in multiple sclerosis.

Authors:  Melih Tutuncu; Junger Tang; Nuhad Abou Zeid; Nilufer Kale; Daniel J Crusan; Elizabeth J Atkinson; Aksel Siva; Sean J Pittock; Istvan Pirko; B Mark Keegan; Claudia F Lucchinetti; John H Noseworthy; Moses Rodriguez; Brian G Weinshenker; Orhun H Kantarci
Journal:  Mult Scler       Date:  2012-06-26       Impact factor: 6.312

Review 3.  White-matter astrocytes, axonal energy metabolism, and axonal degeneration in multiple sclerosis.

Authors:  Melissa Cambron; Miguel D'Haeseleer; Guy Laureys; Ralph Clinckers; Jan Debruyne; Jacques De Keyser
Journal:  J Cereb Blood Flow Metab       Date:  2012-01-04       Impact factor: 6.200

4.  Age and disability accumulation in multiple sclerosis.

Authors:  A Scalfari; A Neuhaus; M Daumer; G C Ebers; P A Muraro
Journal:  Neurology       Date:  2011-09-14       Impact factor: 9.910

5.  Poor early relapse recovery affects onset of progressive disease course in multiple sclerosis.

Authors:  Martina Novotna; M Mateo Paz Soldán; Nuhad Abou Zeid; Nilufer Kale; Melih Tutuncu; Daniel J Crusan; Elizabeth J Atkinson; Aksel Siva; B Mark Keegan; Istvan Pirko; Sean J Pittock; Claudia F Lucchinetti; John H Noseworthy; Brian G Weinshenker; Moses Rodriguez; Orhun H Kantarci
Journal:  Neurology       Date:  2015-07-24       Impact factor: 9.910

6.  Smoking, obesity, and disability worsening in PPMS: an analysis of the INFORMS original trial dataset.

Authors:  Marcus W Koch; Jop Mostert; Pavle Repovic; James D Bowen; Eva Strijbis; Bernard Uitdehaag; Gary Cutter
Journal:  J Neurol       Date:  2021-08-15       Impact factor: 4.849

7.  Reduced creatine kinase B activity in multiple sclerosis normal appearing white matter.

Authors:  Christel Steen; Nadine Wilczak; Johannes M Hoogduin; Marcus Koch; Jacques De Keyser
Journal:  PLoS One       Date:  2010-05-25       Impact factor: 3.240

8.  Evidence for a two-stage disability progression in multiple sclerosis.

Authors:  Emmanuelle Leray; Jacqueline Yaouanq; Emmanuelle Le Page; Marc Coustans; David Laplaud; Joël Oger; Gilles Edan
Journal:  Brain       Date:  2010-04-27       Impact factor: 13.501

9.  Genetic, Immune-Inflammatory, and Oxidative Stress Biomarkers as Predictors for Disability and Disease Progression in Multiple Sclerosis.

Authors:  Ana Paula Kallaur; Edna Maria Vissoci Reiche; Sayonara Rangel Oliveira; Andrea Name Colado Simão; Wildea Lice de Carvalho Jennings Pereira; Daniela Frizon Alfieri; Tamires Flauzino; Caio de Meleck Proença; Marcell Alysson Batisti Lozovoy; Damacio Ramón Kaimen-Maciel; Michael Maes
Journal:  Mol Neurobiol       Date:  2016-01-05       Impact factor: 5.590

10.  Natural history comparisons of primary and secondary progressive multiple sclerosis reveals differences and similarities.

Authors:  Helen Tremlett; Yinshan Zhao; Virginia Devonshire
Journal:  J Neurol       Date:  2009-03-18       Impact factor: 4.849

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.